Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions
- Sponsors Novartis
- 15 Aug 2017 Planned End Date changed from 31 May 2019 to 2 Jul 2019.
- 15 Aug 2017 Planned primary completion date changed from 31 May 2019 to 2 Jul 2019.
- 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.